219 related articles for article (PubMed ID: 25416050)
1. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.
Zhang R; Li Y; Dong X; Peng L; Nie X
Med Oncol; 2014 Dec; 31(12):347. PubMed ID: 25416050
[TBL] [Abstract][Full Text] [Related]
2. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.
Ou Y; Zhai D; Wu N; Li X
Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754
[TBL] [Abstract][Full Text] [Related]
4. miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy.
Yin W; Nie Y; Zhang Z; Xie L; He X
Oncol Rep; 2015 Jul; 34(1):368-74. PubMed ID: 25997995
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer.
Ye Z; Hao R; Cai Y; Wang X; Huang G
Tumour Biol; 2016 Apr; 37(4):4509-15. PubMed ID: 26503209
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1.
He H; Tian W; Chen H; Deng Y
Mol Med Rep; 2016 Feb; 13(2):1923-9. PubMed ID: 26718267
[TBL] [Abstract][Full Text] [Related]
7. miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis.
Zhou S; Huang Q; Zheng S; Lin K; You J; Zhang X
Tumour Biol; 2016 May; 37(5):6837-45. PubMed ID: 26662313
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 Is a Novel Target of miR-26b That Is Associated with the Apoptosis Induced by TRAIL in HCC Cells.
Jiang C; Long J; Liu B; Xie X; Kuang M
Biomed Res Int; 2015; 2015():572738. PubMed ID: 26078955
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1.
Cheng D; Xu Y; Sun C; He Z
Mol Cell Biochem; 2016 Dec; 423(1-2):85-91. PubMed ID: 27686452
[TBL] [Abstract][Full Text] [Related]
11. miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1.
Long J; Ji Z; Jiang K; Wang Z; Meng G
Biomed Res Int; 2015; 2015():373574. PubMed ID: 26526790
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
13. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer.
He H; Tian W; Chen H; Jiang K
Tumour Biol; 2016 Feb; 37(2):1599-607. PubMed ID: 26298722
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Mcl-1 transcription by serum deprivation sensitizes cancer cells to cisplatin.
Senichkin VV; Kopeina GS; Prokhorova EA; Zamaraev AV; Lavrik IN; Zhivotovsky B
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):557-566. PubMed ID: 29203282
[TBL] [Abstract][Full Text] [Related]
15. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
16. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
Lu F; Zhang J; Ji M; Li P; Du Y; Wang H; Zang S; Ma D; Sun X; Ji C
Int J Oncol; 2014 Jul; 45(1):383-92. PubMed ID: 24756163
[TBL] [Abstract][Full Text] [Related]
17. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
Liu Y; Niu Z; Lin X; Tian Y
Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
[TBL] [Abstract][Full Text] [Related]
18. miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes.
Chen W; Du J; Li X; Su J; Huang Y; Ding N; Zhang M; Jiang S
Pharmacogenomics; 2017 Dec; 18(18):1671-1682. PubMed ID: 29173002
[TBL] [Abstract][Full Text] [Related]
19. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
[TBL] [Abstract][Full Text] [Related]
20. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
